alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
exv10w1






Exhibit 10.1




ATHENAHEALTH, INC.

DIRECTOR COMPENSATION PLAN

(Effective July 1, 2011)




     The athenahealth, Inc. (the “Company”) Director Compensation Plan (the “Plan”) applies to
“non-employee” directors. Non-employee directors shall receive the following compensation for
service on the Board of Directors:



Cash Compensation




	 	 	 	 	 
	Meeting Day Fees (1)	 	Meeting Fee
	In Person — Board Meeting
	 	$	3,000	 
	In Person — Committee Meeting
	 	$	3,000	 
	By Phone — Board Meeting and Board Calls
	 	$	1,000	 
	By Phone — Committee Meeting
	 	$	1,000	 
	 
	 	 	 	 





	 	 	 	 	 
	Retainers (2)	 	Annual Retainer
	Lead Director
	 	$	10,000	 
	Audit Committee Chair
	 	$	20,000	 
	Compensation Committee Chair
	 	$	10,000	 
	Litigation Committee Chair
	 	$	10,000	 
	Nominating and Corporate Governance Committee Chair
	 	$	10,000	 








 




			
	(1)	 	Meeting Day Fees are per day or partial day for each meeting attended in person or by
phone and paid quarterly in arrears.
	 
	(2)	 	Retainers are payable quarterly in arrears and pro-rated for any partial period.





Equity Compensation




Annual Grant



Annual equity grants shall be the equivalent in value to $150,000/year. The equity amount will be
determined by dividing $150,000 by the average stock price of the Company during the last 20
trading sessions preceding and including the Annual Meeting date to arrive at a restricted stock
unit equivalent. Restricted stock units and/or stock options (or any combination of stock options
and restricted stock units at a 2:1 ratio) shall be granted with a vesting start date of the first
trading day of July of each year, vesting in one year from the vesting start date. Grants for new
directors will be pro-rated for partial year service and granted on the first business day of the
month following the later of the initial date of service or the date on which such grant is
approved. The number of stock options and restricted stock units will be reviewed annually by the
Nominating and Corporate Governance Committee and are subject to change. Directors with equity
vesting from equity grants granted prior to the effective date of this Director Compensation Plan
will not receive new annual grants until all prior equity grants are fully vested unless an
exception is made by the Nominating and Corporate Governance Committee.



In addition to the cash and equity compensation described above, the Company reimburses each member
of the Board of Directors for reasonable travel and other expenses in connection with attending
meetings of the Board of Directors or committees thereof.



This Plan is prospective from the effective date and will not affect any compensation paid or
granted before that date. This Plan may be amended from time to time by vote of the Board of
Directors. This Plan does not affect the obligations of the Company to indemnify directors as set
forth in relevant sections of the Company’s certificate of incorporation, by-laws or
indemnification agreements. Questions or issues concerning the application and administration of
this Plan will be addressed by the Nominating and Corporate Governance Committee.
### Page 1 of 3 **Disposition Comments Docket No:**  

### FAA - 2013 - 0554 These comments are in **Directorate ID:** 

### 2012 - SW - 009 - AD response to an SNPRM Originating Office Tracking No.: **Next Step:** FRAN SNPRM 

### N o C omments/Only

Supportive Comments Received

– If this box is checked, no signatures are required. No 

### Has the reference d service information been revised since the NPRM was issued? I f ye s, lis t latest revision and attach a cop y. Note that changes beyond the scope of the previously published NPRM will require a new notice. Contact the Directorate focal point for guidance. Instructions: Summarize all comments **by issue** (not by commenter) and provide your recommended resolution of each issue. **All comments relating to the sam e issue should be discussed together.**  Do not list all of the issues from one commenter togeth er. If changes to the AD are required based on the comments received, explain why and describe in detail what change(s) you recommend. Reference FAA - IR- M - 8040.1C Chapter 9. **ISSUE 1:** Select one o

f the following : If other, explain : Commenter(s): What change to the AD action is requested? Why is the change requested or how is it justified? Do we agree? If **YES,** we agree because Make the following changes to the AD: If **PARTIALLY AGREE** , we agree with because We disagree with because

Make the following changes to the AD: If **NO** , we don’t agree because **ISSUE 2**  **:** Select one of the following :

If other, explain : Commenter(s): What change to the AD action is requested? Why is the change requested or how is it justified? Do we agree? If **YES,** we agree because Make the following changes to the AD: If **PARTIALLY AGREE** , we agree with because We disagree with because Make the following changes to the AD:

### Page 2 of 3

If **NO** , we don’t agree because **For additional issues, do uble**  **- click**  **here**

### Page 3 of 3 **S ignature Section**  Signature indicates concurrence with this action. Originating Office Tracking No.: **ASE** Printed Name **: Date** 

**Branch M anager**  **Date**
COURT OF APPEALS

EIGHTH DISTRICT OF TEXAS

EL PASO, TEXAS

ISRAEL FLORES,

 Appellant,

v.

JOSE SANDOVAL,

 Appellee. 

§

§

§

§

§

§

No. 08-15-00302-CV

Appeal from

County Court at Law No. 3

of El Paso County, Texas

(TC # 2014-CCV03062)

J U D G M E N T

The Court has considered this cause on the record and concludes there was no error in the 

judgment. We therefore affirm the judgment of the court below. We further order that Appellee 

recover from Appellant and its sureties, if any, see TEX.R.APP.P. 43.5, on the judgment and all 

costs, both in this Court and the court below for which let execution issue. This decision shall be 

certified below for observance.

IT IS SO ORDERED THIS 5TH DAY OF OCTOBER, 2016.

ANN CRAWFORD McCLURE, Chief Justice

Before McClure, C.J., Rodriguez, and Hughes, JJ.
```

[Congressional Bills 112th Congress]
[From the U.S. Government Publishing Office]
[S. 2848 Introduced in Senate (IS)]

112th CONGRESS
  2d Session
                                S. 2848

To suspend temporarily the duty on cermets for ceramic discharge lamps.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                              May 8, 2012

  Mr. Schumer introduced the following bill; which was read twice and 
                  referred to the Committee on Finance

_______________________________________________________________________

                                 A BILL

 
To suspend temporarily the duty on cermets for ceramic discharge lamps.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. CERMETS FOR CERAMIC DISCHARGE LAMPS.

    (a) In General.--Subchapter II of chapter 99 of the Harmonized 
Tariff Schedule of the United States is amended by inserting in 
numerical sequence the following new heading:

``     9902.01.00        Cermets for         Free            No change      No change      On or before     ''.
                          ceramic discharge                                                 12/31/2015
                          lamps and
                          articles thereof,
                          for use in
                          ceramic discharge
                          lamps (provided
                          for in subheading
                          8113.00.00)......

    (b) Effective Date.--The amendment made by subsection (a) applies 
to goods entered, or withdrawn from warehouse for consumption, on or 
after the 15th day after the date of the enactment of this Act.
                                 <all>
```
# Fourth Court of Appeals

**San Antonio, Texas**

JUDGMENT

No. 04

- 18

- 00428

- CV

FIFTY

- ONE THOUSAND O NE HUNDRED AND TWENT Y

- FOUR DOLLARS in US Currency, et al., Appellant

v.

The STATE of Texas, Appellee

From the 229th Judicial District Court, Starr County, Texas

Trial Court No. DC

- 17

- 658

- A Honorable Jose Luis Garza, Judge Presiding

BEFORE JUSTICE MARTINEZ

, JUSTICE RIOS , AND JUSTICE WATKINS

In accordance with this court’s opinion of this date, the judgment of the trial court is REVERSED, and the cause is R EMANDED to the trial court for a new trial. It is ORDERED that Graciano Garcia, Jr. recover his costs of this appeal from appellee The State of Texas.

SIGNED April 24, 2019.

_____________________________ Rebeca C. Martinez, Justice
EXHIBIT 32.2



CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002



I, Ronald W. Guire, certify, pursuant to 18 U.S.C. Section 1350, as
adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge, the Quarterly Report of Exar Corporation on Form 10-Q for the period ended June 30, 2005 fully complies with the requirements of Section 13(a) or 15(d) of the
Securities Exchange Act of 1934 and that information contained in such Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of Exar Corporation.



Date: August 8, 2005



|                                                  
|--------------------------------------------------
|/s/ RONALD W. GUIRE                               
|Ronald W. Guire                                   
|Executive Vice President, Chief Financial Officer,
|Assistant Secretary and Director                  
|(Principal Financial and Accounting Officer)
II 

112TH CONGRESS 

2D SESSION S. 3159 

To suspend temporarily the duty on acrylic filament tow imported in the 

form of bundles of crimped product, each containing 250,000 filaments 

(plus or minus 10 percent) with an average decitex of 3.3 to 5.6 (plus 

or minus 10 percent) and length greater than 2 meters. 

IN THE SENATE OF THE UNITED STATES 

MAY 10, 2012 

Mrs. HAGAN introduced the following bill; which was read twice and referred 

to the Committee on Finance 

A BILL 

To suspend temporarily the duty on acrylic filament tow 

imported in the form of bundles of crimped product, 

each containing 250,000 filaments (plus or minus 10 

percent) with an average decitex of 3.3 to 5.6 (plus 

or minus 10 percent) and length greater than 2 meters. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 


tjames on DSK6SPTVN1PROD with BILLS
2 

•S 3159 IS

1 SECTION 1. ACRYLIC FILAMENT TOW IMPORTED IN THE 

2 FORM OF BUNDLES OF CRIMPED PRODUCT, 

3 EACH CONTAINING 250,000 FILAMENTS (PLUS 

4 OR MINUS 10 PERCENT) WITH AN AVERAGE 

5 DECITEX OF 3.3 TO 5.6 (PLUS OR MINUS 10 

6 PERCENT) AND LENGTH GREATER THAN 2 

7 METERS. 

8 (a) IN GENERAL.—Subchapter II of chapter 99 of 

9 the Harmonized Tariff Schedule of the United States is 

10 amended by inserting in numerical sequence the following 

11 new heading: 

‘‘ 9902.01.00 Acrylic filament tow 

(polyacrylonitrile tow) containing by weight 92 percent 

or more of polyacrylonitrile, 

not more than 0.01 percent 

of zinc and 2 percent or more 

but not over 8 percent of 

water, imported in the form 

of bundles of crimped product, each containing 250,000 

filaments (plus or minus 10 

percent) with an average 

decitex of 3.3 to 5.6 (plus or 

minus 10 percent) and length 

greater than 2 meters (provided for in subheading 

5501.30.00) ........................... Free No change No change On or before 

12/31/2015 ’’. 

12 (b) EFFECTIVE DATE.—The amendment made by 

13 subsection (a) applies to goods entered, or withdrawn from 

14 warehouse for consumption, on or after the 15th day after 

15 the date of the enactment of this Act. 

Æ 


tjames on DSK6SPTVN1PROD with BILLS
```

[Congressional Bills 112th Congress]
[From the U.S. Government Publishing Office]
[S. 2844 Introduced in Senate (IS)]

112th CONGRESS
  2d Session
                                S. 2844

    To suspend temporarily the duty on certain PCBTF with corrosion 
                               inhibitor.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                              May 8, 2012

  Mr. Schumer introduced the following bill; which was read twice and 
                  referred to the Committee on Finance

_______________________________________________________________________

                                 A BILL

 
    To suspend temporarily the duty on certain PCBTF with corrosion 
                               inhibitor.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. CERTAIN PCBTF WITH CORROSION INHIBITOR.

    (a) In General.--Subchapter II of chapter 99 of the Harmonized 
Tariff Schedule of the United States is amended by inserting in 
numerical sequence the following new heading:

``     9902.01.00      1-Chloro-4-         Free         No change        No change        On or before 12/  ''.
                        (trifluoromethyl)                                                  31/2015.......
                        benzene (CAS No.
                        98-56-6)
                        containing a
                        corrosion
                        inhibitor
                        stabilizer
                        (provided for in
                        subheading
                        2903.99.08 or
                        3824.90.92)......

    (b) Effective Date.--The amendment made by subsection (a) applies 
with respect to goods entered, or withdrawn from warehouse for 
consumption, on or after the 15th day after the date of the enactment 
of this Act.
                                 <all>
```
UNPUBLISHED

UNITED STATES COURT OF APPEALS

FOR THE FOURTH CIRCUIT

No. 97-6926

JEFFREY T. BURNS,

Plaintiff - Appellant,

versus

MRS. BLOUNT,

Defendant - Appellee,

and

RONALD AVERY; LIEUTENANT BATTLE; SERGEANT

BEASLEY; OFFICER JACOBS; OFFICER KRULL,

Defendants.

Appeal from the United States District Court for the Eastern District of North Carolina, at Raleigh. James C. Fox, Chief District

Judge. (CA-95-58-5-F)

Submitted: September 11, 1997 Decided: September 23, 1997

Before RUSSELL, MURNAGHAN, and HAMILTON, Circuit Judges.

Affirmed by unpublished per curiam opinion.

Jeffrey T. Burns, Appellant Pro Se. Reid Russell, PATTERSON,

DILTHEY, CLAY & BRYSON, Raleigh, North Carolina, for Appellee.
2

Unpublished opinions are not binding precedent in this circuit.

See Local Rule 36(c).

PER CURIAM:

Appellant appeals the district court's order denying relief on

his 42 U.S.C. § 1983 (1994) complaint. We have reviewed the record

and the district court's opinions partially accepting the magistrate judge's recommendation and find no reversible error. Accordingly, we affirm on the reasoning of the district court. Burns v.

Blount, No. CA-95-58-5-F (E.D.N.C. Aug. 14, 1996 & June 17, 1997).

We dispense with oral argument because the facts and legal contentions are adequately presented in the materials before the court

and argument would not aid the decisional process.

AFFIRMED
Exhibit
      32.2





**CERTIFICATION
      OF PRINCIPAL FINANCIAL OFFICER**


**UNDER
      SECTION 906 OF THE SARBANES OXLEY ACT OF 2002**


**(Subsections
      (a) and (b) of Section 1350, Chapter 63 of Title 18, United States
      Code)**





In
      connection with the quarterly report on Form 10-Q of GFR Pharmaceuticals, Inc.
      (the “Company”) for the quarter ended March 31, 2008 as filed with the
      Securities and Exchange Commission as of the date hereof (the "Report"), I,
      Zhong Ya Li, the principal financial officer of us, hereby certify, pursuant
      to
      18 U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley
      Act of 2002, that to the best of my knowledge:





(1)
      The
      Report fully complies with the requirements of section 13(a) or 15(d) of the
      Securities Exchange Act of 1934; and





(2)
      The
      information contained in the Report fairly presents, in all material respects,
      the financial condition and result of operations of the Company.





Date:
      May
      19, 2008




/s/
            Zhong
              Ya LiZhong
                Ya Li,
              Principal
                Financial Officer
```

[Congressional Bills 112th Congress]
[From the U.S. Government Publishing Office]
[S. 2955 Introduced in Senate (IS)]

112th CONGRESS
  2d Session
                                S. 2955

 To extend the temporary suspension of duty on mixtures of cyhalothrin 
 (cyclopropanecarboxylic acid, 3-(2-chloro-3,3,3-trifluoro-1-propenyl)-
  2,2-dimethyl-, cyano(3-phenoxyphenyl)methyl ester, [1a(S*), 3a(Z)]-
                           (<plus-minus>)-).

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                              May 8, 2012

 Ms. Klobuchar introduced the following bill; which was read twice and 
                  referred to the Committee on Finance

_______________________________________________________________________

                                 A BILL

 
 To extend the temporary suspension of duty on mixtures of cyhalothrin 
 (cyclopropanecarboxylic acid, 3-(2-chloro-3,3,3-trifluoro-1-propenyl)-
  2,2-dimethyl-, cyano(3-phenoxyphenyl)methyl ester, [1a(S*), 3a(Z)]-
                           (<plus-minus>)-).

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. MIXTURES OF CYHALOTHRIN (CYCLOPROPANECARBOXYLIC ACID, 3-(2-
              CHLORO-3,3,3-TRIFLUORO-1-PROPENYL)-2,2-DIMETHYL-, 
              CYANO(3-PHENOXYPHENYL) METHYL ESTER, [1A(S*), 3A(Z)]-
              (<plus-minus>)-).

    (a) In General.--Heading 9902.02.09 of the Harmonized Tariff 
Schedule of the United States (relating to mixtures of cyhalothrin 
(cyclopropanecarboxylic acid, 3-(2-chloro-3,3,3-trifluoro-1-propenyl)-
2,2-dimethyl-, cyano(3-phenoxyphenyl)methyl ester, [1a(S*), 3a(Z)]-
(<plus-minus>)-)) is amended by striking the date in the effective 
period column and inserting ``12/31/2015''.
    (b) Effective Date.--The amendment made by subsection (a) applies 
with respect to goods entered, or withdrawn from warehouse for 
consumption, on or after the 15th day after the date of the enactment 
of this Act.
                                 <all>
```
Comment Info: =================

General Comment:FAA-2013-0981
STATE of Louisiana v. Lamondre Markes TUCKER

State of Louisiana v. Alicia Ann Tucker

NO. 2015-K-1517

Supreme Court of Louisiana.

April 27, 2018

Reconsideration denied.

CRICHTON, J., recused.
-82 -80 -78 -76 -74 -72

 36

 38

 40

★

▲

▲

▲

▲

★ ▲ ▲ ▲ ▲

 500

 1000

 1500

 100

18 12 06 00

08/03

NOAA HYSPLIT MODEL

 Backward trajectory ending at 2300 UTC 03 Aug 07

 EDAS Meteorological Data

Source

★ at 39.06 N 76.88 W Meters AGL

★

■

■

■

■

★ ■

■ ■

■

★

●

●

●

●

★ ● ● ●

●
```

[Congressional Bills 112th Congress]
[From the U.S. Government Publishing Office]
[S. 312 Introduced in Senate (IS)]

112th CONGRESS
  1st Session
                                 S. 312

   To amend the Patient Protection and Affordable Care Act to repeal 
              certain limitations on health care benefits.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                           February 10, 2011

  Mrs. Hutchison (for herself, Mr. Burr, Mr. Coburn, Mr. Cochran, Ms. 
 Collins, Mr. Inhofe, Mr. Risch, Mr. Wicker, and Mr. Blunt) introduced 
the following bill; which was read twice and referred to the Committee 
                               on Finance

_______________________________________________________________________

                                 A BILL

 
   To amend the Patient Protection and Affordable Care Act to repeal 
              certain limitations on health care benefits.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Patients' Freedom to Choose Act''.

SEC. 2. REPEAL OF DISTRIBUTIONS FOR MEDICINE QUALIFIED ONLY IF FOR 
              PRESCRIBED DRUG OR INSULIN.

    Section 9003 of the Patient Protection and Affordable Care Act 
(Public Law 111-148) and the amendments made by such section are 
repealed; and the Internal Revenue Code of 1986 shall be applied as if 
such section, and amendments, had never been enacted.

SEC. 3. REPEAL OF LIMITATION ON HEALTH FLEXIBLE SPENDING ARRANGEMENTS 
              UNDER CAFETERIA PLANS.

    Sections 9005 and 10902 of the Patient Protection and Affordable 
Care Act (Public Law 111-148) and section 1403 of the Health Care and 
Education Reconciliation Act of 2010 (Public Law 111-152) and the 
amendments made by such sections are repealed.
                                 <all>
```
Exhibit 32

CERTIFICATIONS PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K of NovaMed, Inc. (the Company) for the fiscal year ended December 31, 2006 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Thomas S. Hall, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

| | (1) |  | the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and                               
| | --- |  | ----------------------------------------------------------------------------------------------------------------------------------------------------
| |    
| | (2) |  | the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Thomas S. HallThomas S. HallChief Executive OfficerMarch 16, 2007

In connection with the Annual Report on Form 10-K of NovaMed, Inc. (the Company) for the fiscal year ended December 31, 2006 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Scott T. Macomber, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

| | (1) |  | the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and                               
| | --- |  | ----------------------------------------------------------------------------------------------------------------------------------------------------
| |    
| | (2) |  | the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Scott T. MacomberScott T. MacomberChief Financial OfficerMarch 16, 2007

This certification accompanies this Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

---